| http://dbpedia.org/ontology/abstract
|
Белантамаб мафодотин — конъюгат антитело-препарат для лечения множественной миеломы. Одобрен для применения: ЕС, США (2020).
, Belantamab mafodotin, sold under the brand … Belantamab mafodotin, sold under the brand name Blenrep, is a medication for the treatment of relapsed and refractory multiple myeloma. The most common adverse reactions include keratopathy (corneal epithelium change on eye exam), decreased visual acuity, nausea, blurred vision, pyrexia, infusion-related reactions, and fatigue. Belantamab mafodotin is a humanized IgG1κ monoclonal antibody against the B-cell maturation antigen (BCMA) conjugated with a cytotoxic agent, maleimidocaproyl monomethyl auristatin F (mcMMAF). The antibody-drug conjugate binds to BCMA on myeloma cell surfaces causing cell cycle arrest and inducing antibody-dependent cellular cytotoxicity. Belantamab mafodotin was approved for medical use in the United States and in the European Union in August 2020. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. On November 22, 2022, GSK plc announced it initiated the process for withdrawal of the United States marketing authorization for belantamab mafodotin following the request of the U.S. FDA. This request was based on the outcome of the DREAMM-3 phase III confirmatory trial, which did not meet the requirements of the U.S. FDA Accelerated Approval regulations.U.S. FDA Accelerated Approval regulations.
|
| http://dbpedia.org/ontology/alternativeName
|
Blenrep
|
| http://dbpedia.org/ontology/casNumber
|
2050232-20-5
|
| http://dbpedia.org/ontology/chemicalFormula
|
C6484H10008N1728O2030S44. (C49H66N6O11)4
|
| http://dbpedia.org/ontology/class
|
http://dbpedia.org/resource/Antineoplastic_agent +
|
| http://dbpedia.org/ontology/drugbank
|
DB15719
|
| http://dbpedia.org/ontology/fdaUniiCode
|
DB1041CXDG
|
| http://dbpedia.org/ontology/kegg
|
D11595
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Mafodotin_ADCs.svg?width=300 +
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
https://www.cancer.gov/publications/dictionaries/cancer-drug +
, https://druginfo.nlm.nih.gov/drugportal/name/belantamab%20mafodotin +
|
| http://dbpedia.org/ontology/wikiPageID
|
64771803
|
| http://dbpedia.org/ontology/wikiPageLength
|
12405
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1123317233
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Multiple_myeloma +
, http://dbpedia.org/resource/Food_and_Drug_Administration +
, http://dbpedia.org/resource/B-cell_maturation_antigen +
, http://dbpedia.org/resource/Proteasome_inhibitor +
, http://dbpedia.org/resource/Breakthrough_therapy +
, http://dbpedia.org/resource/Category:GSK_plc_brands +
, http://dbpedia.org/resource/Monomethyl_auristatin_F +
, http://dbpedia.org/resource/Category:Breakthrough_therapy +
, http://dbpedia.org/resource/International_nonproprietary_name +
, http://dbpedia.org/resource/Priority_review +
, http://dbpedia.org/resource/Category:Orphan_drugs +
, http://dbpedia.org/resource/CD38 +
, http://dbpedia.org/resource/Orphan_drug +
, http://dbpedia.org/resource/GSK_plc +
, http://dbpedia.org/resource/Category:Antibody-drug_conjugates +
, http://dbpedia.org/resource/Boxed_warning +
, http://dbpedia.org/resource/Category:Monoclonal_antibodies_for_tumors +
, http://dbpedia.org/resource/Antineoplastic_agent +
, http://dbpedia.org/resource/Intravenous_therapy +
, http://dbpedia.org/resource/First-in-class_medication +
|
| http://dbpedia.org/property/atcPrefix
|
L01
|
| http://dbpedia.org/property/atcSuffix
|
FX15
|
| http://dbpedia.org/property/casNumber
|
2050232
|
| http://dbpedia.org/property/chemicalFormula
|
C6484H10008N1728O2030S44. 4
|
| http://dbpedia.org/property/class
|
http://dbpedia.org/resource/Antineoplastic_agent +
|
| http://dbpedia.org/property/dailymedid
|
Belantamab_mafodotin
|
| http://dbpedia.org/property/drugbank
|
DB15719
|
| http://dbpedia.org/property/kegg
|
D11595
|
| http://dbpedia.org/property/legalEu
|
Rx-only
|
| http://dbpedia.org/property/legalUs
|
Rx-only
|
| http://dbpedia.org/property/mabType
|
mab
|
| http://dbpedia.org/property/routesOfAdministration
|
http://dbpedia.org/resource/Intravenous_therapy +
|
| http://dbpedia.org/property/source
|
zu
|
| http://dbpedia.org/property/synonyms
|
belantamab mafodotin-blmf, GSK2857916
|
| http://dbpedia.org/property/target
|
http://dbpedia.org/resource/B-cell_maturation_antigen +
|
| http://dbpedia.org/property/tradename
|
Blenrep
|
| http://dbpedia.org/property/type
|
mab
|
| http://dbpedia.org/property/unii
|
DB1041CXDG
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Use_American_English +
, http://dbpedia.org/resource/Template:Infobox_drug +
, http://dbpedia.org/resource/Template:Cite_journal +
, http://dbpedia.org/resource/Template:Cite_web +
, http://dbpedia.org/resource/Template:Use_dmy_dates +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:ClinicalTrialsGov +
, http://dbpedia.org/resource/Template:GlaxoSmithKline +
, http://dbpedia.org/resource/Template:Portal_bar +
, http://dbpedia.org/resource/Template:Monoclonals_for_tumors +
, http://dbpedia.org/resource/Template:Drugs.com +
, http://dbpedia.org/resource/Template:Cascite +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Orphan_drugs +
, http://dbpedia.org/resource/Category:Monoclonal_antibodies_for_tumors +
, http://dbpedia.org/resource/Category:Breakthrough_therapy +
, http://dbpedia.org/resource/Category:GSK_plc_brands +
, http://dbpedia.org/resource/Category:Antibody-drug_conjugates +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Belantamab_mafodotin?oldid=1123317233&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Mafodotin_ADCs.svg +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Belantamab_mafodotin +
|
| owl:sameAs |
http://dbpedia.org/resource/Belantamab_mafodotin +
, http://www.wikidata.org/entity/Q98139657 +
, https://global.dbpedia.org/id/Fcb7j +
, http://or.dbpedia.org/resource/%E0%AC%AC%E0%AD%87%E0%AC%B2%E0%AC%BE%E0%AC%A3%E0%AD%8D%E0%AC%9F%E0%AC%BE%E0%AC%AE%E0%AC%BE%E0%AC%AC_%E0%AC%AE%E0%AC%BE%E0%AC%AB%E0%AD%8B%E0%AC%A1%E0%AD%8B%E0%AC%9F%E0%AC%BF%E0%AC%A8 +
, http://ru.dbpedia.org/resource/%D0%91%D0%B5%D0%BB%D0%B0%D0%BD%D1%82%D0%B0%D0%BC%D0%B0%D0%B1_%D0%BC%D0%B0%D1%84%D0%BE%D0%B4%D0%BE%D1%82%D0%B8%D0%BD +
|
| rdf:type |
http://dbpedia.org/ontology/MonoclonalAntibody +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/ontology/Drug +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://www.wikidata.org/entity/Q8386 +
|
| rdfs:comment |
Belantamab mafodotin, sold under the brand … Belantamab mafodotin, sold under the brand name Blenrep, is a medication for the treatment of relapsed and refractory multiple myeloma. The most common adverse reactions include keratopathy (corneal epithelium change on eye exam), decreased visual acuity, nausea, blurred vision, pyrexia, infusion-related reactions, and fatigue. Belantamab mafodotin was approved for medical use in the United States and in the European Union in August 2020. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.ders it to be a first-in-class medication.
, Белантамаб мафодотин — конъюгат антитело-препарат для лечения множественной миеломы. Одобрен для применения: ЕС, США (2020).
|
| rdfs:label |
Belantamab mafodotin
, Белантамаб мафодотин
|
